Implant restores visual perception in blind patients

Article

A subretinal implant has been shown to restore some vision in patients blinded by hereditary retinal degeneration.

A subretinal implant has been shown to restore some vision in patients blinded by hereditary retinal degeneration according to a study published in the Proceedings of The Royal Society B.

The subretinal micro-electrode arrays with 1500 photodiodes was shown to improve visual function from a state of complete blindness enabling recognition of objects up to letters and words..

The research, led by Dr Eberhart Zrenner et al. from the University of Tübingen, was a clinical pilot study examining the efficacy of a light sensitive, externally powered microchip implanted subretinally in three patients with hereditary blindness. The implant contains an array of 1500 active microphotodiodes that each have an amplifier and local stimulation electrode. In addition to this, the tip of the implant contains a further 16 wire-connected electrodes that allow light-independent direct stimulation and testing of the neuron–electrode interface.

Naturally, images are projected through the eye and onto the microphotodiodes through the retina. There was a corresponding pattern produced by the implant sending light-intensity dependent electric stimulation pulses to the patient.

The results demonstrated strong evidence towards the ability of the implant to improve the patient’s visual functions allowing the three patients involved to locate bright objects on a dark table. One patient could even correctly describe and name the shapes as well as finding and approaching persons within a room and reading large letters as complete words.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.